---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-011130"
form_type: "8-K"
ticker: "MRK"
cik: "0000310158"
company_name: "Merck & Co., Inc."
filed_at: "2022-02-03T23:59:59+00:00"
generated_at: "2026-06-27T11:57:32.348727+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Merck Q4 2021 revenue $13.5B (+24%), Non-GAAP EPS $1.80; FY2022 guidance issued

## Summary
- Q4 2021 sales $13.5B (+24% YoY); GAAP EPS $1.51, Non-GAAP EPS $1.80 (vs $0.98).
- Full-year 2021 sales $48.7B (+17%); GAAP EPS $4.86, Non-GAAP EPS $6.02.
- KEYTRUDA FY sales $17.2B (+20%); GARDASIL/GARDASIL 9 sales $5.7B (+44%).
- Molnupiravir contributed $952M in Q4; Animal Health sales $5.6B (+18%).
- FY2022 guidance: sales $56.1-$57.6B, GAAP EPS $5.76-$5.91, Non-GAAP EPS $7.12-$7.27.

## SEC filing metadata
- accession: 0001104659-22-011130
- form_type: 8-K
- ticker: MRK
- cik: 0000310158
- company_name: Merck & Co., Inc.
- filed_at: 2022-02-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310158/000110465922011130/0001104659-22-011130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310158/000110465922011130/tm222755d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-011130
- JSON: https://secwatch.observer/filing/0001104659-22-011130.json
- Plain text: https://secwatch.observer/filing/0001104659-22-011130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.